Voltage-gated sodium channel alpha subunit family (Nav1.x) (Nav1.x)

Voltage-gated sodium channels (Nav1.x) are critical transmembrane proteins responsible for the rapid influx of sodium ions that initiates and propagates action potentials in excitable cells, such as neurons, skeletal muscle, and cardiac myocytes (Catterall, 2012). The Nav1.x family comprises nine distinct alpha-subunit isoforms (Nav1.1 through Nav1.9), which are encoded by the SCN1A through SCN11A genes and exhibit specific tissue distribution and kinetic properties (StatPearls, 2023). These channels consist of a large pore-forming alpha subunit that can be associated with one or more auxiliary beta subunits which modulate channel trafficking and gating (UniProt, 2024). Dysfunctions in these channels, often due to genetic mutations, lead to a variety of "channelopathies" including epilepsy, cardiac arrhythmias like Brugada syndrome, and chronic pain disorders such as erythromelalgia (PubMed, PMC3424717). Pharmacologically, Nav1.x channels are the targets of several classes of drugs, including local anesthetics, class I antiarrhythmics, and many anticonvulsants (Bagal et al., 2015). These therapeutic agents generally work by blocking the ion-conducting pore or stabilizing the inactivated state, thereby reducing cellular hyperexcitability (PubChem, 2024). Modern drug discovery efforts are increasingly focused on developing isoform-selective inhibitors, particularly for Nav1.7 and Nav1.8, to provide targeted analgesia without the dose-limiting central nervous system or cardiovascular side effects associated with non-selective blockers (Nature Reviews Drug Discovery, 2018).

Other names

SCN familyVoltage-dependent sodium channelSodium channel protein type alpha subunitVGSCVoltage-gated sodium channel alpha subunit

Inhibition of sodium ion influx by blocking the channel pore or stabilizing the inactivated state to reduce cellular excitability.